Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its antibody-drug conjugate (ADC), BL-M14D1, intended for the treatment of advanced solid tumors.
BL-M14D1 leverages the same “linker+toxin” platform as another ADC developed by Biokin Pharma, BL-B01D1, which is currently pursuing a dual listing in Hong Kong. This platform is a testament to the company’s commitment to innovation in targeted cancer therapies.- Flcube.com
